Bristol-Myers Squibb, Gilead Sciences and Merck & Co., Inc. Announce Plans to Develop Fixed-Dose Combination of Three HIV Medicines.

Business Wire › May 16, 2004

Linked as:

Extract

Bristol-Myers Squibb, Gilead Sciences and Merck & Co., Inc. Announce Plans to Develop Fixed-Dose Combination of Three HIV Medicines.

Business Editors/Health/Medical Writers

BIOWIRE2K

NEW YORK & FOSTER CITY, Calif. & WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--May 16, 2004--

Companies Support U.S. Department of Health and Human Services'

Call to Increase Treatment Options for HIV in Developing World

Bristol-Myers Squibb Company (NYSE:BMY), Gilead Sciences, Inc. (Nasdaq:GILD) and Merck & Co., Inc. (NYSE:MRK) announced today that they are in discussions on the development of a once-daily, fixed-dose combination of three anti-HIV drugs and are also considering certain co-packaging options for the individual products. The three companies welcome today's comments by U.S. Secretary of Health and Human Services Tommy Thompson on the need for increased treatment option...

See the full content of this document